The EHMT1 Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the AGS human gastric adenocarcinoma cell line. This polyclonal pool contains diverse gene-disrupted alleles, providing a robust loss-of-function model for interrogating EHMT1-dependent processes. The knockout model is generated via CRISPR/Cas9-mediated disruption, enabling assessment of population-level phenotypes such as proliferation, migration, and drug response in a physiologically relevant epithelial cancer context.
AGS cells, derived from a patient with diffuse-type gastric adenocarcinoma, serve as a standard epithelial model in gastric cancer research. These adherent cells maintain gastric epithelial characteristics, express wild-type TP53, and exhibit robust tumorigenicity in xenograft models. They are extensively used to study signaling pathways, epigenetic regulation, and therapeutic responses in gastric carcinogenesis. Their compatibility with molecular and imaging-based approaches, including transfection and lentiviral transduction, facilitates detailed mechanistic and drug-sensitivity investigations.
EHMT1 (GLP) encodes a histone methyltransferase that catalyzes H3K9 mono- and dimethylation (H3K9me1/me2), creating repressive chromatin marks. EHMT1 functions in a complex with EHMT2 (G9a) and is recruited by transcription factors such as ATF3 and MYC downstream of AKT signaling. H3K9me1/me2 is bound by HP1 proteins, which scaffold DNMT1, DNMT3A, and MBD1 to reinforce DNA methylation and gene silencing. Critical downstream targets include the tumor suppressors CDH1 (E-cadherin) and CDKN1A (p21), whose repression promotes proliferation and invasion in gastric cancer cells. Thus, EHMT1 integrates chromatin modification with transcriptional control in pathways including Wnt signaling.
In AGS gastric cancer cells, EHMT1 is often overexpressed and contributes to epigenetic silencing of tumor suppressors, correlating with poor prognosis. This polyclonal knockout model enables dissection of EHMT1’s role in cell proliferation, colony formation, and invasiveness. By eliminating EHMT1, researchers can assess re-activation of silenced genes, changes in global H3K9 methylation, and the interplay between histone and DNA methylation machineries. The model also provides a platform for testing EHMT inhibitors aimed at reversing H3K9me-mediated repression, offering a path toward epigenetic therapy discovery.
Typical experimental workflows include ChIP-qPCR to profile H3K9me1/me2 at promoters of CDH1 and CDKN1A, RNA-seq for de-repressed target discovery, and Western blotting to validate EHMT1 depletion. Cell-based functional readouts such as proliferation, colony formation, and migration/invasion assays characterize the loss-of-function phenotype. Drug sensitivity screening with EHMT inhibitors leverages this model for preclinical epigenetic drug evaluation. For additional technical details or to discuss custom gene-editing services, please contact Ascent Research.
